Kornimate/medical-research-clean huggingface dataset:
liver fibrosis in sickle cell disease

Conditions: Sickle Cell Disease

Summary: patients with sickle cell disease many have a number of systemic complications, including liver problems. some of these liver problems lead to liver fibrosis/cirrhosis, secondary to chronic blood transfusions. the purpose of this study is to investigate fibroscan readings in patients with sickle cell disease and iron overload secondary to blood transfusions, and to correlate the fibroscan results with ferriscan. a comparison with the results of fibroscan to patients with sickle cell without known liver disease, who have never been on chronic transfusions and with normal liver function profiles will also be made.the primary hypothesis is that the results of fibroscan will correlate with the results of ferriscan and liver biopsy.

liver biopsy is the gold standard to examine the liver for iron deposits and histology. however, liver biopsy is invasive and involves a risk of bleeding and pain. biopsy may also miss significant pathology if the small biopsy specimen is taken from an uninvolved part of the liver. non-invasive techniques such as mri are now used to evaluate the liver iron content. mri can visualize the whole liver and measure liver iron content. mri, however, will not detect liver scarring. liver transient elastography (fibroscan) is a non-invasive ultrasound tool for assessing liver fibrosis or scarring by measuring liver stiffness (lsm). compared with liver biopsy, fibroscan provides immediate results and is a painless, short (3 mins), simple procedure to perform. in some studies fibroscan reports have correlated well with liver biopsy results of fibrosis and cirrhosis, and with ferriscan, ferritin and liver function tests. this purpose of this study is to investigate the role of fibroscan in individuals with sickle cell anemia and iron overload or who have a diagnosis of liver disease, and to compare fibroscan readings with magnetic resonance imaging. we will also compare the results of the fibroscan with liver biopsy. this study will also compare the results of fibroscan to patients with sickle cell without any known liver disease, who have never been on chronic transfusions (defined as no more than 4 transfusions in lifetime) and who have normal liver function profiles.

Eligibility criteria:
inclusion criteria: * pediatric patients age 10 years and older with sickle cell disease * meeting other criteria: 1. history of chronic transfusion and iron overload and/or 2. known liver disease related to sickle cell or iron overload * signed consent and assent (as applicable) exclusion criteria: * children younger than 10 years * pregnant females * prisoners * other causes of liver disease, unrelated to sickle cell or iron overload inclusion criteria for controls: * patients 10 years and older with sickle cell disease without history of chronic transfusions (less than 4 transfusions in a lifetime) * and without obvious liver disease.

Keywords: sickle cell disease hemochromatosis liver fibrosis liver cirrhosis fibroscan ferriscan liver iron
qualitative interviews with healthcare professionals

Conditions: Total Knee Replacement

Summary: planning phase- qualitative interviews with healthcare professionals to assist in the development of a new patient reported outcome measure (prom) to assess patient's emotional wellbeing, and perceptions of total knee replacement (tkr) surgery for the treatment of knee arthritis.

the interviews for the sync01-pp-usa project will be conducted in person at the american association of hip and knee surgeons (aahks) annual conference in dallas, texas, usa during the 3rd, 4th, and 5th november 2022. the interviews will take approximately 30 minutes.

Eligibility criteria:
inclusion criteria: * healthcare professionals who currently care for patients who have undergone total knee replacement surgery. * healthcare professionals who, in the opinion of the investigator, can understand the project, co-operate with the interview process and are willing to be interviewed in person. * healthcare professionals who are able to give voluntary, written informed consent to participate in this project and from whom consent has been obtained.

Keywords: tkr
plethysmography opto-electronic and asthma

Conditions: Asthma

Summary: objective: to assess the influence of nebulization with bronchodilators carried by the heliox coupled to pep in the distribution of compartimental lung volumes in asmathic adults and to correlate with pulmonary function data. methods: a controlled randomized trial involving 27 patients divided into four groups: heliox + pep, oxygen + pep, heliox and oxygen. after the initial evaluation, it was placing 89 reflective markers attached to the surface of the trunk and images acquired by optoelectronic plethysmography (oep) of six cameras. three slow vital capacity maneuvers and quiet breathing regarded as phase control. after the control phase, all patients underwent nebulization with a distribution noninvasive system, semi-closed using 10 drops of fenoterol bromide and 20 drops of ipratropium.


Eligibility criteria:
inclusion criteria: * the study included individuals diagnosed with moderate to severe asthma with forced expiratory volume in one second (fev1) \<60% or fev1 \<60% - 80% predicted; * showing reversibility of bronchial obstruction after administration of bronchodilators at least 10% in fev1. exclusion criteria: * unable to understand or perform the spirometric maneuver; * with a history of smoking; * pulmonary comorbidities as chronic obstructive pulmonary disease (copd); * bronchiectasis and tuberculosis sequel; * hemodynamic instability defined as heart rate (hr) greater than 150 bpm or systolic blood pressure below 90 mmhg or greater than 150mmhg; * pregnancy and any contraindication to the use of peep; * such as increased work of breathing (acute asthma); * active hemoptysis; * acute sinusitis; * pneumothorax; * untreated; surgery or facial trauma; * oral or injury; * epistaxis; * nausea and esophageal surgery.
role of citicoline in treatment of newborns with hypoxic ischemic encephalopathy

Conditions: Hypoxic-Ischemic Encephalopathy

Summary: citicoline, is a naturally occurring compound and an intermediate in the metabolism of phosphatidylcholine. phosphatidylcholine is an important component of the phospholipids of the cell membranes. citicoline is composed of two molecules: cyti¬dine and choline. both these molecules enter the brain separately and by passing through the blood-brain barrier where they act as substrates for intracellular synthesis of cdp-choline . this drug has been widely used in adults who suffer from acute ischemic strokes for than 4 decades with good results and has been proved to have a very good safety profile as well. it has various therapeutic effects at several stages of the ischemic cascade in acute ischemic stroke. 1. it stabilizes cell membranes by increasing phosphatidylcholine and sphingomyelin synthesis and by inhibiting the release of free fatty acids . by protecting membranes, citicoline inhibits glutamate release during ischemia. in an experimental model of ischemia in the rat, citicoline treatment decreased glutamate levels and stroke size. 2. citicoline favors the synthesis of nucleic acids, proteins, acetylcholine and other neurotransmitters, and decreases free radical formation therefore, citicoline simultaneously inhibits different steps of the ischemic cascade protecting the injured tissue against early and delayed mechanisms responsible for ischemic brain injury. 3. citicoline may facilitate recovery by enhancing synaptic outgrowth and increased neuroplasticity with decrease of neurologic deficits and improvement of behavioral performance. considering these pharmacologic properties of citicoline, we are planning to see its effects in newborns who have hie which causes a global acute ischemic changes in developing brain.


Eligibility criteria:
inclusion criteria: * • newborn babies having grade 2 and 3 hie, of both genders delivered in labor room or operation theatre of our hospital. * outdoor patients presenting within 24 hours of delivery exclusion criteria: * • outborn babies presenting after 24 hours of delivery. * patients with severe congenital malformations * babies born extremely prematurely (less than 28 weeks)
the active mind study

Conditions: Cognitive Impairment; Cardiovascular Risk Factor

Summary: the purpose of this study is to explore whether physical exercise, mindfulness training, or both interventions together can improve cognitive function in individuals with multiple risk factors for the development of dementia in the future.

the investigators will test the feasibility and acceptability of a combined mindfulness training + aerobic training intervention, vs. either alone or none to improve cognitive function in older adults with cognitive impairment. the investigators will also obtain estimates of effect sizes (and confidence intervals) on cognitive function. preliminary analyses will be conducted to explore the mediating role of changes in aerobic capacity, physical activity, vascular risk factors, and mindfulness skills. assessments will be conducted at baseline, 3-, and 6- months since baseline.

Eligibility criteria:
inclusion criteria: 1. age ≥55 2. being physically inactive (defined as not meeting current aha recommendations for physical activity, i.e., \< 150 min of moderate-intensity aerobic activity per week or \< 75 minutes of vigorous aerobic activity per week 3. cognitive complaint defined as answering yes to the question "do you feel that your memory or thinking skills have gotten worse recently?" 4. fluency in english language exclusion criteria: 1. unwillingness/inability to provide informed consent 2. contraindications to physical activity as per the participant's pcp assessment 3. blood pressure \>200/110 4. severe depressive symptoms (defined as hospital anxiety and depression scale \[hads\] depression subscale scores \>14) 5. acute psychosis (from medical record) 6. severe cognitive impairment (mini-mental state examination \[mmse\] score \<24) 7. recent hospitalization (\< 6 weeks) 8. current (at least once a month) mind/body practice (i.e., mindfulness meditation, yoga, or tai chi)

Keywords: mindfulness exercise cognitive function
evaluation of adjuvant hormonal treatment for 24 months after radical prostatectomy in high risk of recurrence patients.

Conditions: Metastases

Summary: principal objective: evaluation of effectiveness in terms of survival without metastases to 10 years, of adjuvant hormonal treatment with leuprorelin acetate (eligard® 45 mg) for 24 months after radical prostatectomy in patients with high risk of recurrence. secondary objective(s): * psa evolution * evaluation of testosterone level * specific survival * overall survival * tolerance * quality of life (qlq-c30 questionnaires)


Eligibility criteria:
inclusion criteria: 1. patients who have received the information leaflet and signed the consent form 2. ≥18 years of age with a life expectancy of at least 10 years 3. performance status (ecog) ≤2 4. radical prostatectomy (rp) with or without extended pelvic lymphadenectomy in the 3 months preceding inclusion 5. histologically confirmed prostatic adenocarcinoma 6. patients r0, n0 or nx or n+ (≤ 2 nodes among nodes removed), m0 and with at least one of the following criteria: * postoperative gleason score \>7 * postoperative gleason score =7 with the presence of high-grade gleason patterns * pt3b patients 7. postoperative psa \<0.1 ng/ml (dosage perform within 2 months after surgery) 8. neutrophils ≥1500/mm³, platelets ≥100000/mm³ 9. bilirubin ≤ upper normal limit (this will not apply to subjects with gilbert's syndrome, persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of evidence of hemolysis or hepatic pathology); asat and alat ≤1.5 times upper normal limit; creatinine \ 60 ml/min) 10. patients affiliated to a social security scheme exclusion criteria: 1. previous treatments for prostatic adenocarcinoma (ht or orchiectomy or ct) 2. presence of metastases: * positive bone scintigraphy, including patients with medullary compression and/or * abdominal-pelvic ct scan or mri showing lymph node and/or visceral involvement 3. history of cancer, with the exception of basal cell carcinoma or any other cancer treated in the 5 years before inclusion and in complete remission 4. incompatible concomitant treatment(s) 5. hypersensitivity to other gnrh agonists and/or any of the excipients of eligard® 6. any illness or problem including geographic, psychiatric or psychological which is incompatible with being monitored during the trial 7. persons deprived of their freedom or under supervision (including guardianship), 8. patients already included in another therapeutic trial with an experimental drug or having been given an experimental drug within a period of 30 days

Keywords: benefit of adjuvant treatment prostatectomy
expanded treatment protocol (etp) of ruxolitinib in patients with polycythemia vera who were hydroxyurea resistant or intolerant and for whom no treatment alternatives was available.

Conditions: Polycythemia Vera

Summary: the purpose of this open-label, single arm, multi-center expanded treatment protocol (etp) was to provide early access to ruxolitinib and evaluate safety information in patients with polycythemia vera (pv) who were hydroxyurea (hu) resistant or intolerant and who had no other standard treatment option, nor did they qualify for another clinical study for pv


Eligibility criteria:
inclusion criteria: •confirmed diagnosis of pv according to the 2008 world health organization criteria, palpable spleen, resistant to or intolerant of hydroxyurea, ecog performance status of 0, 1 or 2; did not have access to a comparable or satisfactory alternative treatment exclusion criteria: •inadequate liver or renal function, significant bacterial, fungal, parasitic, or viral infection requiring treatment, active malignancy within the past 5 years, except treated cervical intraepithelial neoplasia, basal cell carcinoma of the skin, or squamous cell carcinoma of the skin, with no evidence for recurrence in the past 3 years., women who were pregnant or nursing.

Keywords: polycythemia vera hematologic diseases myeloproliferative disorders inc424 ruxolitinib hydroxyurea resistant adult
the circadian rhythm of potassium and cystatin c

Conditions: Cardiac Arrhythmias; Sudden Cardiac Death

Summary: the potassium value is important to prevent cardiac arrhythmias and sudden cardiac death. in patients with renal failure, the potassium value is not stable and tends to raise. until now there are no data available if the potassium value has a circadian rhythm and if there are individual changes from day to day.

potassium and cystatin c is measured every 2 hours during 24 hours, twice. there are two groups of patients: patients with egfr \ 60 ml/min

Eligibility criteria:
inclusion criteria: * at least 18 years old * normal renal function and impaired renal function (gfr \< 60 ml/min) respectively exclusion criteria: * pregnancy * anaemia (hb\<10 mg/dl)

Keywords: change of potassium amount, circadian and day-to-day variability
elobixibat colonic motor function study

Conditions: Chronic Idiopathic Constipation

Summary: this is a randomized trial of 36 otherwise healthy patients with chronic idiopathic constipation. the purpose of the study is to compare the effects of daily single-dose oral elobixibat and placebo for 7 days on colonic motor effects.


Eligibility criteria:
inclusion criteria: * male or female 18-65 years of age * body mass index of 18-40 kg/m2 * diagnosis of constipation for 12 or more weeks with symptom onset at least 6 months prior to the diagnosis and insufficient criteria to fulfill a diagnosis of irritable bowel syndrome (ibs), as defined by the rome iii criteria for functional constipation * stable concomitant medications defined as no changes in regimen for at least 2 weeks prior to the trial period exclusion criteria: * structural or metabolic diseases/conditions that affect the gastrointestinal system, or functional gastrointestinal (gi) disorders. * use of drugs or agents within the past 2 weeks that alter gi transit including laxatives, magnesium or aluminum-containing antacids, prokinetics, erythromycin, narcotics, anticholinergics, tricyclic antidepressants, selective serotonin reuptake inhibitor and newer antidepressants * use of drugs or agents within the past 2 weeks that may add drowsiness and central nervous system (cns) depression such as barbiturates, benzodiazepines, ethanol, lithium, opioids, buspirone, antihistamines, muscle relaxants, and other cns depressants * the patient has a history of bariatric surgery for treatment of obesity; surgery to remove a segment of the gi tract; or surgery of the abdomen, pelvic or retroperitoneal area during the 6 months prior to screening; or appendectomy or cholecystectomy 3 months prior to screening; or other major surgery 1 month prior to screening * clinical evidence (including physical exam) of clinically significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurological, psychiatric, or other disease that interfere with the objectives of the trial. any candidate participants with such disorder mentioned will be referred to their general physician * the hospital anxiety and depression scale (hads) will be used to exclude patients with significant affective disorders
hospital management of hyperglycemia study of insulin glargine plus insulin lispro versus human regular insulin

Conditions: Hyperglycemia

Summary: the purpose of this study is to compare the use of insulin glargine plus insulin lispro to human regular insulin for treatment of hyperglycemia in the hospital setting in patients without known prior history of diabetes.

this study involves a comparison of 2 methods for administering subcutaneous insulin therapy to non-critically ill adult patients with hyperglycemia and without known history of diabetes who are admitted to non-intensive care unit (icu) general medical hospital services. basal-bolus therapy, considered the gold standard for glucose control in patients with known diabetes, will be compared with sliding scale insulin, a commonly used method of glucose control (prevailing standard practice) in hospitalized patients. in this study, basal-bolus therapy will consist of once-daily glargine plus lispro 3 to 4 times daily adjusted to achieve pre-meal capillary plasma glucose \<140 milligrams per deciliter (mg/dl) and bedtime capillary plasma glucose \<180 mg/dl for patients who are eating \[predose plasma glucose \<140 mg/dl for patients with nil per os (npo) orders\]; sliding scale insulin will be administered using human regular insulin 4 times daily as needed adjusted to achieve predose capillary plasma glucose target \<140 mg/dl in patients who are eating or have npo orders.

Eligibility criteria:
major inclusion criteria: * no known history of diabetes * admission or pre-entry plasma glucose (pg) level between 140 and 400 mg/dl * non-critically ill and admitted to acute care medical services * have a body mass index greater than or equal to 18.5 kg/m\^2 and less than or equal to 45 kilograms per square meter (kg/m\^2) major exclusion criteria: * received any insulin/analog therapy for longer than 108 hours prior to study entry or intermediate- or long-acting insulin/analogs (neutral protamine hagedorn, detemir, or glargine) in the 24 hours prior to randomization or any intravenous insulin therapy prior to randomization * laboratory evidence of diabetic ketoacidosis for patients with pre-randomization pg greater than 250 mg/dl * have taken any oral or injectable antihyperglycemic medications other than insulin within 3 months prior to study entry * have acute critical illness or are expected to require admission to an icu or equivalent or be treated with glucocorticoid therapy during the hospital study period * expected hospitalization less than 24 hours post-randomization

Keywords: hyperglycemia diabetes hospital diabetic
deep learning for histopathological classification and prognostication of gynaecologic smooth muscle tumours

Conditions: Stump

Summary: smooth muscle tumors of the uterus that do not fit the diagnostic criteria of benignity (such as leiomyomas) or malignancy (such as leiomyosarcomas) are called stump (smooth muscle tumor of uncertain malignant potential). a potential solution to this problem could be the application of predictive models using artificial intelligence (ai) to aid in the histopathological classification and prognosis of gynecological smooth muscle tumors. deep learning using convolutional neural networks represents a specific class of machine learning, in which predictive models are trained by considering small groups of pixels in digital images and iteratively identifying salient features. in this study, we aim to develop deep learning models capable of accurately subclassifying and predicting the prognosis of gynecological smooth muscle tumors, based on histopathological features of hematoxylin and eosin (h\&e) slides. the aim is to develop a diagnostic and prognostic algorithm to help pathologists better classify and diagnose uterine smooth muscle tumors and predict their clinical course.


Eligibility criteria:
inclusion criteria: * patients with a diagnosis of uterine smooth muscle tumors (leiomyomas, smooth muscle tumors of uncertain malignancy and leiomyosarcomas), registered in the rreps database and/or treated at institut bergonié or one of the participating centers. * histopathological material available (kerosene blocks and/or slides). exclusion criteria: * na

Keywords: algorithm diagnostic pronostic
mechanisms underlying abnormal ambulatory bp patterns

Conditions: Cardiovascular Diseases; Heart Diseases; Hypertension

Summary: to understand the mechanism(s) underlying sodium-dependent blood pressure control, and to determine the consequences thereof.

background: the blood pressure of a significant percentage of the hypertensive population, and the normotensive population at a high risk for the development of hypertension (blacks and older individuals), is sodium (salt)-dependent. that is to say, increasing the intake of salt will increase blood pressure in these individuals; conversely, and more importantly, decreasing the intake of salt will reduce blood pressure. design narrative: the investigators believed that the mechanisms responsible for sodium-dependent blood pressure were only indirectly linked to race, sex, and age. their research was consistent with the hypothesis that sodium-dependent blood pressure control resulted from decreased responsiveness of the renal and adrenal blood pressure regulatory systems. this produced abnormal daily blood pressure patterns, with reduced fluctuation resulting in extended periods of increased blood pressure. the increased cardiovascular load led to the early development of cardiovascular and renal disease, including hypertension. they tested this hypothesis by identifying 'high risk' and 'normal risk' subjects based on renal responses to sodium restriction. the subjects were equal numbers of healthy males and females, blacks and whites, between the ages of 55-70 years. using an innovative approach, they then examined the influence of risk status on 24-hour patterns of blood pressure, hormonal activity, and sodium handling. finally, they determined the clinical significance of the profiles by examining changes in cardiac and renal status at a two-year follow-up. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria